Message #24 From:
Stock News Bot Date: January 16, 2007 06:49:00 AM
NPHC News Nutra Pharma Sponsors Educational Website for Adrenomyelonueropathy (AMN)
BOCA RATON, Fla.--(BUSINESS WIRE)--Nutra Pharma Corp. (OTCBB:NPHC), a biotechnology company that is
developing drugs for HIV and Multiple Sclerosis has today announced that
it has sponsored AMNhelp.com, a website dedicated to educating patients
and providing information about Adrenomyeloneuropathy (AMN).
“Although there is currently no approved
treatment for AMN, we felt that it is important to educate patients
about this disease and to provide information about current treatment
research,” explained Rik J Deitsch, Chairman
and CEO of Nutra Pharma Corporation. “The
sponsorship of AMNhelp.com coincides with our progression into a Phase
IIb human clinical trial for the treatment of AMN,”
he added.
The AMNhelp.com website will feature information about
Adrenomyeloneuropathy: its symptoms, diagnosis, treatment research, and
links to regional, national, and international support groups.
“AMN is a rare inherited metabolic disorder,
but still interests the wider neurologic community because of its
similarities to Multiple Sclerosis,” commented
Stewart Lonky, MD, a member of the board of directors of Nutra Pharma
Corporation. “AMN is often misdiagnosed and
confused with Multiple Sclerosis and it is our hope that the AMNhelp.com
website will help educate the public about the differences between the
two diseases,” he concluded.
RPI-78M is ReceptoPharm's lead drug candidate for the treatment of
neurological and autoimmune disorders. The drug has already completed
pre-clinical testing and a Phase I/IIa human trial in AMN. In October,
ReceptoPharm received Ethics Committee approval in the UK to begin its
Phase IIb human clinical trial for the treatment of AMN.
About Nutra Pharma Corp.
Nutra Pharma Corp. is a biopharmaceutical company specializing in the
acquisition, licensing and commercialization of pharmaceutical products
and technologies for the management of neurological disorders, cancer,
autoimmune and infectious diseases. Nutra Pharma Corp. through its
subsidiaries carries out basic drug discovery research and clinical
development and also seeks strategic licensing partnerships to reduce
the risks associated with the drug development process. The Company's
holding, ReceptoPharm, Inc, is developing technologies for the
production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's
subsidiary, Designer Diagnostics is engaged in the research and
development of diagnostic test kits designed to be used for the rapid
identification of infectious diseases such as Tuberculosis (TB) and
Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to
identify and acquire intellectual property and companies in the
biotechnology arena.
This press release contains forward-looking statements. The words or
phrases "would be," "will allow," "intends to," "will likely result,"
"are expected to," "will continue," "is anticipated," "estimate,"
"project," or similar expressions are intended to identify
"forward-looking statements." Actual results could differ materially
from those projected in Nutra Pharma's ("the Company") business plan.
The Company's business is subject to various risks, which are discussed
in the Company's filings with the Securities and Exchange Commission
("SEC").The sponsorship of AMNhelp.com should not be
construed as an indication in any way whatsoever of the value of the
Company or its common stock.The Company's filings may be
accessed at the SEC's Edgar system at www.sec.gov.Statements made herein are as of the date of this press release and
should not be relied upon as of any subsequent date. The Company
cautions readers not to place reliance on such statements. Unless
otherwise required by applicable law, we do not undertake, and we
specifically disclaim any obligation, to update any forward-looking
statements to reflect occurrences, developments, unanticipated events or
circumstances after the date of such statement.
